Tools
Stock profile

EXELIXIS, INC. (EXEL)

EXEL · Latest close $68.29 as of Nov 18, 2026 · 13F data as of Jun 30, 2026 (2026 Q2)
Latest close
$68.29
As of Nov 18, 2026
Tracked funds holding
1 of 149
2026 Q2 13F filings
Opened / added
0 / 0
vs previous quarter
Trimmed / exited
0
vs previous quarter

EXELIXIS, INC. (EXEL) is held by 1 of 149 tracked super-investor funds (144 filed in Q2) in 2026 Q2 13F filings. Latest close $68.29 as of Nov 18, 2026.

Data as of Nov 18, 2026 (prices) · 2026 Q2 13F filings (quarter ended Jun 30, 2026) · Latest Form 4: none in the last 90 days · Congress to Nov 16, 2026.

Funds
2026 Q2 13F
Fundamentals
Revenue · FY2026
Red flags
none flagged
Short interest
as of Oct 15, 2026
Holdings · Charts · All institutions · Fundamentals · Short interest · Fails to deliver · Insider trading · 5% holders · Planned sales · Politician trading · Committee jurisdiction · Government relations · Screens & lenses · Signal record · Related stocks · Recent 8-K

Funds holding this

First Eagle Investment Management — 1 tracked fund hold EXEL. See all holders.

Insider and Congress activity

No insider open-market activity or Congress trades reported for this stock in the recent window. Insider trading · Politician trading.

Often held alongside

AMGEN INC (AMGN) · GILEAD SCIENCES, INC. (GILD) · Taysha Gene Therapies, Inc. (TSHA) · BIOGEN INC. (BIIB) · Immunovant, Inc. (IMVT) — stocks the same funds also hold. See all related stocks.

Super-investor holdings · 2026 Q2

FundPortfolio weightSharesChange vs prev. quarter
First Eagle Investment Management<0.01%10,000HELD Q3 filed Nov 10

Source: SEC Form 13F filings, quarter ended Jun 30, 2026. Change labels compare each fund’s 2026 Q2 filing with its previous filing. Fund counts aggregate every share class mapped to this ticker.

Price change since quarter-end: +27.0% from the close on the first trading day after the quarter ended (Jul 1, 2026) to the latest close (Nov 17, 2026). 13F does not report purchase prices — this is the price change since the quarter-end close, not a gain on any fund’s actual purchase.

Filing season: the Q3 2026 13F tracker follows every tracked fund’s filing for the quarter ended Sep 30, 2026, with its biggest buys and sells.

Charts

72.7530.772024-11-192026-11-18

Closing prices (unadjusted for dividends), last 2 years — 501 trading days to Nov 18, 2026. Dashed lines mark 13F filing deadlines. Source: Yahoo Finance daily bars.

All institutions · Form 13F

Institutions holding756 of 8,857 filers
Long-only filers among them752
Change vs 2026 Q1+69 net · 701 entered · 632 exited
Shares reported, all filers258,875,197
Reported value, all filers$13.3B

Source: SEC Form 13F data sets — every filer's latest report for the quarter ended Jun 30, 2026, not just the tracked funds above; changes compare with the quarter ended Mar 31, 2026. Share counts and values are summed as reported in the filings (a small number of filers report values in thousands of dollars, so value totals are as-filed sums).

Company fundamentals

ExchangeNasdaq
IndustryBiological Products, (No Diagnostic Substances) (SIC 2836)
Revenue · FY2026$2.3B
Net income · FY2026$782.6M
Total assets · FY2026$2.8B
Shares outstanding244,010,895
Market cap (at latest close)$16.7B

Source: SEC EDGAR company filings (submissions and company facts), collected Oct 30, 2026. Shares outstanding as reported Oct 19, 2026.

Short interest

Shares short · Oct 15, 202627,313,139
Share of shares outstanding11.19%
Days to cover11.33

Shares short at recent settlements — Jul 31, 2026: 28.7M · Aug 14, 2026: 28.0M · Aug 31, 2026: 28.7M · Sep 15, 2026: 26.4M · Sep 30, 2026: 28.2M · Oct 15, 2026: 27.3M.

Source: FINRA Equity Short Interest (biweekly settlement data). Shares outstanding from SEC filings as of Oct 19, 2026.

Fails to deliver

Shares failed to deliver · Oct 14, 20260
Share of shares outstanding0.00%
Fails as a share of short interest · Oct 15, 20260.0%

Fails to deliver at recent settlements — Jul 31, 2026: 619 · Aug 14, 2026: 0 · Aug 31, 2026: 0 · Sep 15, 2026: 0 · Sep 30, 2026: 0 · Oct 14, 2026: 0.

Source: SEC Fails-to-Deliver data (semi-monthly files, published about two weeks after each settlement date). Each figure is the balance of shares not yet delivered on that date; a stock absent from that date’s file counts as zero. See our research on whether fails to deliver predict returns. Shares outstanding from SEC filings as of Oct 19, 2026.

Insider trading · Form 4

Data unavailable — no Form 4 transactions for this ticker were parsed in the last 90 days.

Planned sales · Form 144

FiledSellerRoleShares to sellMarket valueApprox. sale dateSource
Aug 10, 2026MARY BECKERLEDirector9,812$526.5KAug 10, 2026SEC filing
Jun 1, 2026Eckhardt Sue GailDirector9,812$499.1KJun 1, 2026SEC filing
Jun 1, 2026JACK L WYSZOMIERSKIDirector3,925$198.4KJun 1, 2026SEC filing
May 26, 2026DANA T AFTABOfficer43,451$2.2MMay 26, 2026SEC filing
May 20, 2026PATRICK JOSEPH HALEYOfficer32,110$1.6MMay 20, 2026SEC filing
May 18, 2026CHRISTOPHER J SENNEROfficer34,901$1.7MMay 18, 2026SEC filing
May 18, 2026BRENDA JOY HEFTIOfficer6,625$332.6KMay 18, 2026SEC filing
May 14, 2026BOMBORA RISE FOUNDATIONFamily foundation of the CEO of EXEL.100,000$5.1MMay 14, 2026SEC filing
May 7, 2026MARY BECKERLEDirector7,712$373.6KMay 7, 2026SEC filing
May 7, 2026GEORGE H POSTEDirector60,000$2.7MMay 7, 2026SEC filing

A Form 144 notice is a planned sale, not a completed sale. Most recent first. Source: SEC Form 144 filings, 63,013 notices from Apr 13, 2023 to Oct 9, 2026.

Activist disclosure · Schedule 13D

FiledFormPrice change since disclosure
Aug 14, 2026SCHEDULE 13D/A+30.9% (close Aug 17, 2026 → Nov 17, 2026)

Reference close is the first trading day after the filing (Aug 17, 2026). A Schedule 13D reports beneficial ownership, not a purchase — there is no transaction price to show. Source: SEC EDGAR Schedule 13D filings.

5% holders · Schedule 13D/G

FiledFilerFormShares% ownedEvent dateSource
Aug 14, 2026Farallon Capital Management, L.L.C.SC 13D/A13,989,0105.6%Aug 14, 2026SEC filing
Aug 12, 2026AQR Capital Management, LLCSC 13G/A11,023,9434.4%Jun 30, 2026SEC filing
Apr 29, 2026Vanguard Capital ManagementSC 13G13,233,2475.1%Mar 31, 2026SEC filing
Mar 26, 2026The Vanguard GroupSC 13G/A00.0%Mar 13, 2026SEC filing
Feb 13, 2026AQR Capital Management, LLCSC 13G13,658,3885.1%Dec 31, 2025SEC filing
Jan 5, 2026Farallon Capital Partners, L.P.SC 13D/A1,189,3340.4%Jan 1, 2026SEC filing
May 20, 2025Farallon Capital Partners, L.P.SC 13D/A1,537,9550.6%May 16, 2025SEC filing
Apr 28, 2025BlackRock, Inc.SC 13G/A28,499,47010.2%Mar 31, 2025SEC filing
Mar 5, 2025Farallon Capital Partners, L.P.SC 13D/A1,738,4200.6%Mar 5, 2025SEC filing

One filing is one row; a filing may list several reporters and the first is shown. Figures are as filed, including amendments that report zero shares after a transfer. Source: SEC Schedule 13D/G filings, 57,443 filings parsed to Oct 2, 2026.

Politician trading · U.S. Congress

Data unavailable — no congressional STOCK Act transactions for this ticker were parsed in the current window (as of Nov 16, 2026).

Committee jurisdiction

Industry: Biological Products, (No Diagnostic Substances) (SIC 2836). Standing committees with jurisdiction over this industry: Senate Committee on Health, Education, Labor, and Pensions, House Committee on Energy and Commerce.

None of the members who traded this stock in the current window sit on these committees.

Assignments are the current (119th Congress) rosters. A trade made in an earlier Congress may have been made under a different assignment. Jurisdiction is by industry (SEC SIC code), not by anything the company said or did. Same rule as our committee-jurisdiction study.

Government relations

Lobbying: 126 Lobbying Disclosure Act filings named this company as client, 2018–2026; most common issues: Health Issues (119), Medicare/Medicaid (69), Taxation/Internal Revenue Code (33).

Federal contracts: no obligated amounts found for this ticker (USASpending, fiscal years 2021–2026).

Lobbying filings are matched by company core name; a filing can match more than one ticker. Contract amounts are obligated amounts (money committed, not money spent), matched by recipient name — contracts under a subsidiary’s name can be missed. Sources: Senate Lobbying Disclosure Act filings; USAspending.gov. See Methodology.

Screens & lenses

Financial Screens

· Growth — Revenue up every year for 5 straight years

· Graham — Sound finances and a long run of profits

· Greenblatt Magic Formula — High earnings yield and high return on capital together

· Earnings Quality (Cash Conversion) — Profits that actually come back as cash

Chart Signals

· Monthly Uptrend — Price above its 12-month moving average

· Top Relative Strength — Top 20% of the universe by 6-month return

Key figures

· Growth — Latest revenue: $2.3B · 5-yr revenue CAGR: 15.7% · Straight growth years: 8

· Graham — Current ratio: 3.56 · Straight profitable years: 8 · Debt ratio: 0.10 · Latest net income: $782.6M

· Greenblatt Magic Formula — Earnings yield: 4.6% · Return on capital: 76.7% · Combined rank: 71

· Earnings Quality (Cash Conversion) — Cash conversion (3-yr avg): 1.36 · Operating cash flow: $884.3M · Net income: $782.6M

Financial screens are computed from SEC company financial statements; red-flag models are screens, not verdicts — see Methodology.

Also held by the tracked funds that hold EXEL — ranked by lift, the co-holding pattern described in Methodology: AMGEN INC (AMGN) · GILEAD SCIENCES, INC. (GILD) · Taysha Gene Therapies, Inc. (TSHA) · BIOGEN INC. (BIIB) · Immunovant, Inc. (IMVT) · REPLIGEN CORP (RGEN) · BIO-TECHNE Corp (TECH) · Vaxcyte, Inc. (PCVX).

8 of the 8 are same-industry (SIC) fillers: fewer than 4 stocks met the lift rule for this stock.

Recent 8-K filings

FiledItemsSource
Oct 29, 20262.02 Results of Operations and Financial Condition · 9.01 Financial Statements and ExhibitsSEC filing
Sep 11, 20268.01 Other EventsSEC filing
Aug 31, 20268.01 Other EventsSEC filing

Source: SEC EDGAR Form 8-K filings, latest first. Amendments (Form 8-K/A) are labeled as such. Item labels are the SEC's item titles; a filing can carry several items. Item 5.02 covers both departures and appointments, which this index does not distinguish.

Related

AMGEN INC (AMGN) · Track Record: how the signals scored · Practice timing on EXEL

One email a week: the week’s new filings and research. Subscribe free

← EXE  ·  EXI →

Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.